Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 09:15 ET | Source: Cellectis Inc.

Cellectis to Present a Development Update for eti-cel at ASH 2025

Preliminary data recently shared for eti-cel (UCART20x22) show an 86% ORR and a 57% CR rate (n=7), underscoring its potential to improve outcomes in r/r NHLPreclinical data demonstrated that combining...
November 03, 2025 09:15 ET | Source: Marker Therapeutics

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data MT-601 demonstrated robust safety profile with no dose...
November 03, 2025 09:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition

Agios today announced that new data on mitapivat, an oral pyruvate kinase activator, will be featured in oral and poster presentations during ASH
February 19, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Oncology Conference Coverage — Stay Ahead in the Oncology Domain with Real-time Coverage from AACR, ESMO, ASCO, ASH, EHA, and Others | DelveInsight

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oncology Conference Coverage — Stay Ahead in the Oncology Domain with Real-time Coverage from AACR, ESMO, ASCO, ASH, EHA, and Others | DelveInsight ...
December 09, 2024 21:00 ET | Source: Lyell Immunopharma, Inc

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

Objective response rate (ORR) of 94% and a complete response (CR) rate of 71% demonstrated after IMPT-314 treatment in CAR T-naïve patients with large B-cell lymphoma who had received at least 2 prior...
December 09, 2024 07:00 ET | Source: Secura Bio

New Combination Data of Secura Bio’s COPIKTRA® (duvelisib) Presented at the 2024 American Society of Hematology Meeting

Dr. Alison Moskowitz presented results of a Phase 1 study of combination duvelisib plus ruxolitinib in relapsed/refractory (R/R) peripheral T-cell lymphoma or cutaneous T-cell lymphoma Results...
December 09, 2024 07:00 ET | Source: Secura Bio

Secura Bio Presented New Data from its Phase 2 PRIMO Trial of Copiktra® (Duvelisib) in Relapsed or Refractory Peripheral T-cell Lymphoma and Announced Plans for its Phase 3 TERZO Trial at the 2024 American Society of Hematology Meeting

Data from the Phase 2 PRIMO trial in 123 patients showed an overall response rate (ORR) of 48%, a complete response (CR) rate of 33%, and a median duration of response (DOR) of 7.89 months The...
December 05, 2024 20:00 ET | Source: Shanghai EpimAb Biotherapeutics Co., Ltd.

EpimAb Biotherapeutics Announces Oral Presentation for EMB-06 (CND106) First-in-human (FIH) Phase I Study in Multiple Myeloma at the American Society of Hematology (ASH) 2024 Annual Meeting

SHANGHAI, Dec. 06, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a global clinical stage biotechnology company specializing in the development of bispecific antibodies, is pleased to announce the...
November 26, 2024 05:00 ET | Source: ImCheck Therapeutics SAS

ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Annual Meeting

ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Annual Meeting Marseille, France, November 26, 2024, 11 am CET –...
November 05, 2024 09:30 ET | Source: Lyell Immunopharma, Inc

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for...